Long-term electrocardiographic findings in patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation.
Haghjoo M.
J Electrocardiol. 2007 Oct;40(4):357.e1-2. doi: 10.1016/j.jelectrocard.2007.04.005.
Retrospective Analysis of Risk Factors for Related Complications of Chemical Ablation on Hypertrophic Obstructive Cardiomyopathy.
Li CY, Shi YQ.
Arq Bras Cardiol. 2019 Apr;112(4):432-438. doi: 10.5935/abc.20190060. Epub 2019 Apr 1.
Delayed electrocardiographic changes after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
Guo H, Wang P, Xing Y, Peng F, Jiang J, Yang B, You B, Qiu Y, Lee JD.
J Electrocardiol. 2007 Oct;40(4):356.e1-6. doi: 10.1016/j.jelectrocard.2006.12.003. Epub 2007 Feb 20.
In percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy, it is not the speed of intracoronary alcohol injection but the amount of alcohol injected that determines the resultant infarct size.
Cheng TO.
Circulation. 2004 Jul 20;110(3):e23; author reply e23. doi: 10.1161/01.CIR.0000135537.69990.0F.
Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.
Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S.
J Am Coll Cardiol. 1998 Feb;31(2):252-8. doi: 10.1016/s0735-1097(97)00508-1.
Cardiac troponin I degradation in serum of patients with hypertrophic obstructive cardiomyopathy undergoing percutaneous septal ablation.
Madsen LH, Lund T, Grieg Z, Nygaard S, Holmvang L, Jurlander B, Grande P, Christensen G, Atar D.
Cardiology. 2009;114(3):167-73. doi: 10.1159/000226596. Epub 2009 Jul 2.
A Clinical Study of Precision Chemoablation for Hypertrophic Obstructive Cardiomyopathy Without Large Interventricular Septal Branches.
Cao X, Huang R, Geng H, Liu H, Gu Y, Xu P, Chen Y, Yao J, Sheng H.
Clin Cardiol. 2025 Mar;48(3):e70095. doi: 10.1002/clc.70095.
Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area.
Faber L, Seggewiss H, Ziemssen P, Gleichmann U.
Catheter Cardiovasc Interv. 1999 Aug;47(4):462-6. doi: 10.1002/(SICI)1522-726X(199908)47:4<462::AID-CCD16>3.0.CO;2-9.
Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation.
van der Lee C, Scholzel B, ten Berg JM, Geleijnse ML, Idzerda HH, van Domburg RT, Vletter WB, Serruys PW, ten Cate FJ.
Am J Cardiol. 2008 May 1;101(9):1315-20. doi: 10.1016/j.amjcard.2008.01.003. Epub 2008 Mar 10.
Percutaneous transluminal septal myocardial ablation in hypertrophic cardiomyopathy.
van der Lee C, Foley DP, Vletter WB, Ten Cate FJ, Kofflard MJ.
Neth Heart J. 2001 May;9(2):75-77.
